Diabetic Macular Edema Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) February 24, 2015 -- The report “Diabetic Macular Edema – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Diabetic Macular Edema. Diabetic macular edema is swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision mutilation. Common symptoms of diabetic macular edema are blurry vision, floaters, double vision and eventually blindness. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/diabetic-macular-edema-pipeline-review-h1-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for diabetic macular edema and special features on late-stage and discontinued projects. Companies discussed in this Diabetic Macular Edema – Pipeline Review, H1 2015 report include ActiveSite Pharmaceuticals, Inc., Acucela Inc., Aerpio Therapeutics, Inc., Alcon, Inc., Allergan, Inc., AlphaMab Co., Ltd, Ampio Pharmaceuticals, Inc., Astellas Pharma Inc., Auven Therapeutics Management L.L.L.P, Avalanche Biotechnologies, Inc., Eleven Biotherapeutics Inc., F. Hoffmann-La Roche Ltd., Foamix Pharmaceuticals Ltd., Gene Signal International SA, Genmab A/S, GlaxoSmithKline plc, Icon Bioscience, Inc., Kala Pharmaceuticals, Inc., Kowa Company, Ltd., Mabion SA, MacuCLEAR, Inc., Molecular Design International, Inc., NicOx S.A., Ohr Pharmaceutical Inc., Pfizer Inc., Quark Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., SciFluor Life Sciences, LLC, Senju Pharmaceutical Co., Ltd., ThromboGenics NV.
Drugs profile discussed in this report include 49-B, abicipar pegol, aganirsen, AKB-9778, ALG-1001, Antibodies to Inhibit Hemopexin for Diabetic Macular Edema, ASP-440, ASP-8232, AVA-101, conbercept, danazol, darapladib, dexamethasone acetate nanoparticle, dexamethasone dipropionate, difluprednate, Drug for Diabetic Macular Edema, Drugs to Inhibit Tyrosine Kinase for Ophthalmology, EBI-029, EBI-031, emixustat hydrochloride, KVD-001, LKA-651, loteprednol etabonate, MC-4001, minocycline Gel, MTP-131, NCX-422, NCX-434, nesvacumab, ocriplasmin (recombinant), Peptide for Diabetic Macular Edema, PF-04634817, PF-655, ranibizumab, ranibizumab biosimilar, ranibizumab biosimilar, ripasudil, RX-10045, SF-0166, squalamine lactate, teprotumumab. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=307275 . (This is a premium report priced at US$2000 for a single user License.)
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of content
List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2015
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Acucela Inc., H1 2015
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Alcon, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Allergan, Inc., H1 2015
Diabetic Macular Edema - Pipeline by AlphaMab Co., Ltd, H1 2015
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H1 2015
Diabetic Macular Edema - Pipeline by Auven Therapeutics Management L.L.L.P, H1 2015
Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Eleven Biotherapeutics Inc., H1 2015
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Diabetic Macular Edema - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2015
Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2015
Diabetic Macular Edema - Pipeline by GlaxoSmithKline plc, H1 2015
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H1 2015
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2015
Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Molecular Design International, Inc., H1 2015
Explore more reports on Diabetes Drugs Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/diabetes-drugs .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article